ArticleFrontiers in immunology2024

Identification of beneficial populations for targeted-immunotherapy combinations: tailoring later-line care for patients with pMMR/MSS metastatic colorectal cancer.

Dan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.